Last reviewed · How we verify
Cohort 1 CTAP101 Capsules- 60µg
Cohort 1 CTAP101 Capsules- 60µg is a Small molecule drug developed by OPKO Health, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Cohort 1 CTAP101 Capsules- 60µg |
|---|---|
| Sponsor | OPKO Health, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort 1 CTAP101 Capsules- 60µg CI brief — competitive landscape report
- Cohort 1 CTAP101 Capsules- 60µg updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI
Frequently asked questions about Cohort 1 CTAP101 Capsules- 60µg
What is Cohort 1 CTAP101 Capsules- 60µg?
Cohort 1 CTAP101 Capsules- 60µg is a Small molecule drug developed by OPKO Health, Inc..
Who makes Cohort 1 CTAP101 Capsules- 60µg?
Cohort 1 CTAP101 Capsules- 60µg is developed by OPKO Health, Inc. (see full OPKO Health, Inc. pipeline at /company/opko-health-inc).
What development phase is Cohort 1 CTAP101 Capsules- 60µg in?
Cohort 1 CTAP101 Capsules- 60µg is in Phase 2.
Related
- Manufacturer: OPKO Health, Inc. — full pipeline
- Compare: Cohort 1 CTAP101 Capsules- 60µg vs similar drugs
- Pricing: Cohort 1 CTAP101 Capsules- 60µg cost, discount & access